What makes agents fundamentally different from each other from the viewpoint of a 10-month-old infant? While infants at this age can already individuate human-like objects from non-humanlike ones and self-propelled agents from inert objects, little is known of when and how they start individuating within the domain of agents. What is clear from previous studies is that differences in surface and dynamic features are not sufficient. We hypothesized that mental properties-in this case the agents' preferences-can serve as an individuating property. In our study, we familiarized infants with two animated agents who had different preferences. The agents sequentially and repeatedly emerged from behind an occluder, and then each agent approached one of two target objects before returning behind the occluder. After familiarization, the occluder was lifted, revealing either one agent or two agents. While infants successfully individuated the agents in the preference-demonstration condition, they failed to do so in the exposure-only condition in which perceptually similar surface and dynamic features of the agents were presented but without indicating preferences. Our study thus provides evidence that mental properties can help individuate agents, grounding the claim that infants understand agents as mental entities at their core.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/infa.12472 | DOI Listing |
Am J Sports Med
January 2025
Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Background: The efficacy of bone marrow aspirate concentrate (BMAC) in promoting bone-tendon interface (BTI) healing without any carriers remains a subject of debate.
Purpose: To evaluate BMAC effects with different carriers on tendon regeneration in a rabbit model of chronic rotator cuff tear.
Study Design: Controlled laboratory study.
Infect Agent Cancer
January 2025
Shahid Beheshti University of Medical Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Both women and men are now confronted with the grave threat of cancers caused by the human papillomavirus (HPV). It is estimated that 80% of women may encounter HPV over their lives. In the preponderance of cases involving anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical malignancies, high-risk HPV (HR-HPV) is the causative agent.
View Article and Find Full Text PDFBMC Res Notes
January 2025
Laboratory of Health and Life Science, Graduate School of Health and Sports Science, Juntendo University, Inzai, 270-1695, Japan.
Objective: Dictyostelium differentiation-inducing factors 1 and 3 [DIF-1 (1) and DIF-3 (2), respectively], along with their derivatives, such as Ph-DIF-1 (3) and Bu-DIF-3 (4), demonstrate antibacterial activity in vitro against Gram-positive bacteria, including methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive Enterococcus faecalis (VSE), and vancomycin-resistant Enterococcus faecium [VRE (VanA)]. This study investigates the therapeutic potential of DIF compounds against these Gram-positive bacteria.
View Article and Find Full Text PDFJ Anesth Analg Crit Care
January 2025
Department of Anesthesia and Intensive Care, Agostino Gemelli IRCCS University Polyclinic Foundation, Rome, Italy.
Background: Neuromuscular blocking agents (NMBAs) are routinely used in anesthesia practice. An undetected, incomplete recovery of neuromuscular function at the end of surgery potentially exposes patients to clinical deterioration in the postoperative period. The aim of this study was to investigate the incidence of postoperative residual neuromuscular blockade (RNMB) in a cohort of patients receiving NMBAs.
View Article and Find Full Text PDFVirol J
January 2025
Virology Laboratory, Faculty of Life Sciences and Biotechnology, South Asian University (SAU), New Delhi, 110068, India.
Maturation inhibitors (MIs) block HIV-1 maturation by preventing the cleavage of the capsid protein and spacer peptide 1 (CA-SP1). Bevirimat (BVM), a first-in-class MI, displayed sub-optimal efficacy in clinical trials due to presence of SP1:V7A polymorphism in the Gag protein.This polymorphism is inherently present in HIV-1 subtype C and conferred resistance to BVM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!